Zevra Therapeutics, Inc.— Sankey Diagram
Annual mode · period ending 2025-12-31 · SEC EDGAR
FY2025 - Q4(Oct 25 · Nov 25 · Dec 25)
Total Assets
$285M
↑+59.8% +$107Mvs FY2024
Total Liabilities
$130M
↓-6.1% -$8Mvs FY2024
Equity
$155M
↑+289.9% +$115Mvs FY2024
Cash
$62M
↑+84.7% +$29Mvs FY2024
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $285M | $178M |
| Current Assets | $223M | $86M |
| Cash | $62M | $34M |
| ST Investments | $0 | $0 |
| Receivables | $0 | $10M |
| Inventory | $2M | $2M |
| Other Current | $159M | $40M |
| Non-Current Assets | $62M | $92M |
| PPE | $489K | $356K |
| Goodwill | $5M | $5M |
| Intangibles | $6M | $69M |
| Investments | $0 | $0 |
| Other Non-Current | $50M | $18M |
| Total Liab+Eq | $285M | $178M |
| Current Liab. | $39M | $34M |
| Accounts Payable | $2M | $13M |
| Short-Term Debt | $0 | $0 |
| Deferred Revenue | $0 | $0 |
| Other CL | $37M | $21M |
| Non-Current Liab. | $91M | $104M |
| Long-Term Debt | $62M | $60M |
| Other LT Liab. | $29M | $45M |
| Equity | $155M | $40M |
| Retained Earnings | $422M | $505M |
| Other Equity | $0 | $0 |
QuarterCharts · SEC EDGAR data · ZVRA · Comparing FY2025 vs FY2024